Vonapanitase - Proteon Therapeutics

Drug Profile

Vonapanitase - Proteon Therapeutics

Alternative Names: PRT 201

Latest Information Update: 08 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Proteon Therapeutics
  • Class Elastases; Recombinant proteins
  • Mechanism of Action Extracellular matrix protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Vascular disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Vascular disorders
  • Phase I Peripheral arterial disorders

Most Recent Events

  • 09 May 2018 Proteon plans to file a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for Vascular disorders in 2020
  • 08 May 2018 Proteon Therapeutics announces intention to submit BLA to US FDA for Vascular disorders in the second half of 2019
  • 05 Mar 2018 Proteon Therapeutics completes enrolment in the phase III PATENCY-2 trial for Vascular disorders in USA and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top